Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences:

• The Alzheimer’s Association International Conference (AAIC), in San Diego and virtually, from Sunday, July 31, to Thursday, August 4, 2022
  • Acumen scientists will present a poster, “Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics,” (P4-178) on August 3

• The BTIG Biotech Conference, in New York and virtually, on Monday, August 8, 2022 at 2:00 pm ET
  • Dr. Eric Siemers, Chief Medical Officer, will be participating in an AD panel: “The Next Generation of Anti-Amyloid and Anti-Tau Targeting Therapeutics for Alzheimer's Disease”

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, headquartered in Charlottesville, Va. with clinical operations based in Carmel, Ind., is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on toxic soluble AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Contacts:

Media:
AcumenPR@westwicke.com

Investors:
investors@acumenpharm.com

FAQ

What is Acumen Pharmaceuticals presenting at the AAIC conference?

At the Alzheimer’s Association International Conference (AAIC) on August 3, 2022, Acumen Pharmaceuticals will present a poster titled 'Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics.'

When is Acumen Pharmaceuticals participating in the BTIG Biotech Conference?

Acumen Pharmaceuticals will participate in the BTIG Biotech Conference on August 8, 2022, at 2:00 pm ET.

Who will represent Acumen Pharmaceuticals at the BTIG Biotech Conference?

Dr. Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, will participate in a panel discussing Alzheimer's therapeutics.

What is the focus of Acumen Pharmaceuticals' product candidate ACU193?

ACU193 is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, currently undergoing Phase 1 clinical trials for early Alzheimer's disease.

What type of company is Acumen Pharmaceuticals?

Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing novel therapeutics for Alzheimer's disease.